The use of whole tumour lysate with its vast amount of characterized and uncharacterized T-cell epitopes available for activating CD4+ T helper and CD8+ cytotoxic lymphocytes simultaneously offers distinct advantages in tumour vaccine preparation [29]. Here, CD4 is linked to neoplasm.